| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Androgen Antagonists | 75 | 2022 | 1269 | 9.440 |
Why?
|
| Prostatic Neoplasms | 161 | 2018 | 10525 | 9.330 |
Why?
|
| Gonadotropin-Releasing Hormone | 47 | 2015 | 1188 | 6.360 |
Why?
|
| Bone Neoplasms | 55 | 2019 | 2579 | 5.890 |
Why?
|
| Antineoplastic Agents, Hormonal | 48 | 2017 | 1521 | 5.820 |
Why?
|
| Diphosphonates | 41 | 2016 | 616 | 5.240 |
Why?
|
| Bone Density Conservation Agents | 37 | 2016 | 789 | 5.000 |
Why?
|
| Leuprolide | 13 | 2015 | 309 | 3.370 |
Why?
|
| Toremifene | 10 | 2013 | 24 | 3.330 |
Why?
|
| Orchiectomy | 29 | 2015 | 456 | 3.320 |
Why?
|
| Anilides | 13 | 2016 | 422 | 3.070 |
Why?
|
| Osteoporosis | 31 | 2012 | 1556 | 2.980 |
Why?
|
| Imidazoles | 24 | 2016 | 1268 | 2.980 |
Why?
|
| Prostate-Specific Antigen | 36 | 2018 | 2245 | 2.350 |
Why?
|
| Phenylthiohydantoin | 5 | 2017 | 192 | 2.250 |
Why?
|
| RANK Ligand | 10 | 2013 | 318 | 1.980 |
Why?
|
| Bone Density | 28 | 2012 | 3395 | 1.630 |
Why?
|
| Prednisone | 15 | 2019 | 1556 | 1.620 |
Why?
|
| Fractures, Bone | 19 | 2019 | 1849 | 1.540 |
Why?
|
| Antineoplastic Agents | 32 | 2022 | 13714 | 1.510 |
Why?
|
| Neoplasms, Hormone-Dependent | 12 | 2014 | 414 | 1.410 |
Why?
|
| Thiohydantoins | 2 | 2018 | 20 | 1.320 |
Why?
|
| Body Composition | 12 | 2014 | 2393 | 1.290 |
Why?
|
| Nitriles | 13 | 2017 | 950 | 1.280 |
Why?
|
| Osteoclasts | 9 | 2012 | 751 | 1.280 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2016 | 117 | 1.240 |
Why?
|
| Goserelin | 5 | 2015 | 128 | 1.180 |
Why?
|
| Adenocarcinoma | 11 | 2014 | 6338 | 1.110 |
Why?
|
| Bone and Bones | 14 | 2014 | 2567 | 1.000 |
Why?
|
| Pyridines | 6 | 2016 | 2862 | 1.000 |
Why?
|
| Male | 196 | 2022 | 349524 | 0.990 |
Why?
|
| Tosyl Compounds | 7 | 2008 | 117 | 0.960 |
Why?
|
| Double-Blind Method | 27 | 2021 | 11877 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2022 | 11253 | 0.860 |
Why?
|
| Prostatectomy | 13 | 2016 | 1800 | 0.850 |
Why?
|
| Aged | 111 | 2021 | 161488 | 0.830 |
Why?
|
| Castration | 4 | 2013 | 151 | 0.790 |
Why?
|
| Radium | 3 | 2019 | 55 | 0.780 |
Why?
|
| Bone Diseases | 4 | 2010 | 423 | 0.780 |
Why?
|
| Aged, 80 and over | 58 | 2021 | 58184 | 0.770 |
Why?
|
| Cardiovascular Diseases | 19 | 2015 | 14075 | 0.770 |
Why?
|
| Spinal Fractures | 3 | 2011 | 688 | 0.760 |
Why?
|
| Androgens | 12 | 2022 | 1216 | 0.740 |
Why?
|
| Neoplasm Metastasis | 21 | 2019 | 5112 | 0.720 |
Why?
|
| Bone Remodeling | 8 | 2016 | 592 | 0.710 |
Why?
|
| Humans | 202 | 2022 | 708843 | 0.660 |
Why?
|
| Collagen Type I | 7 | 2016 | 576 | 0.650 |
Why?
|
| Disease-Free Survival | 16 | 2018 | 7026 | 0.630 |
Why?
|
| Antibodies, Monoclonal | 9 | 2011 | 9584 | 0.610 |
Why?
|
| Diabetes Mellitus | 8 | 2014 | 5348 | 0.570 |
Why?
|
| Diabetes Complications | 3 | 2013 | 1394 | 0.560 |
Why?
|
| Pyrazoles | 2 | 2021 | 1954 | 0.550 |
Why?
|
| Flutamide | 4 | 2015 | 95 | 0.550 |
Why?
|
| Oligopeptides | 2 | 2011 | 1276 | 0.550 |
Why?
|
| Neoplastic Cells, Circulating | 8 | 2016 | 862 | 0.540 |
Why?
|
| Osteoblasts | 5 | 2013 | 1192 | 0.540 |
Why?
|
| Fractures, Spontaneous | 5 | 2015 | 240 | 0.540 |
Why?
|
| Middle Aged | 83 | 2021 | 213752 | 0.530 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1136 | 0.520 |
Why?
|
| Urogenital Neoplasms | 3 | 2012 | 140 | 0.520 |
Why?
|
| Digital Rectal Examination | 2 | 2012 | 44 | 0.490 |
Why?
|
| Myostatin | 1 | 2014 | 125 | 0.490 |
Why?
|
| Insulin Resistance | 9 | 2013 | 3866 | 0.470 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 279 | 0.450 |
Why?
|
| Disease Progression | 24 | 2017 | 13298 | 0.450 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2016 | 5405 | 0.450 |
Why?
|
| Testosterone | 10 | 2017 | 2352 | 0.440 |
Why?
|
| Prostate | 5 | 2015 | 1564 | 0.440 |
Why?
|
| Sarcopenia | 2 | 2013 | 304 | 0.420 |
Why?
|
| Alkaline Phosphatase | 7 | 2014 | 892 | 0.420 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 1896 | 0.420 |
Why?
|
| Treatment Outcome | 39 | 2017 | 61932 | 0.410 |
Why?
|
| Benzamides | 5 | 2017 | 1406 | 0.410 |
Why?
|
| Androstenes | 5 | 2015 | 167 | 0.410 |
Why?
|
| Kallikreins | 3 | 2017 | 267 | 0.390 |
Why?
|
| Thiazolidinediones | 2 | 2004 | 484 | 0.390 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2014 | 398 | 0.380 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2006 | 130 | 0.380 |
Why?
|
| Quality of Life | 6 | 2021 | 11594 | 0.380 |
Why?
|
| Absorptiometry, Photon | 5 | 2012 | 1692 | 0.380 |
Why?
|
| Metabolic Diseases | 2 | 2014 | 648 | 0.370 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1632 | 0.370 |
Why?
|
| Peptides | 8 | 2016 | 4424 | 0.370 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 652 | 0.370 |
Why?
|
| Taxoids | 8 | 2016 | 655 | 0.360 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 860 | 0.350 |
Why?
|
| Hormone Antagonists | 1 | 2008 | 110 | 0.340 |
Why?
|
| Veterans | 2 | 2012 | 2288 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 605 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2016 | 8877 | 0.340 |
Why?
|
| Body Mass Index | 6 | 2014 | 12366 | 0.340 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 321 | 0.330 |
Why?
|
| Pyrrolidines | 2 | 2006 | 342 | 0.320 |
Why?
|
| Androstadienes | 3 | 2013 | 345 | 0.310 |
Why?
|
| Obesity | 6 | 2013 | 12031 | 0.310 |
Why?
|
| Clinical Trials as Topic | 12 | 2013 | 8024 | 0.300 |
Why?
|
| Steroids | 2 | 2012 | 880 | 0.290 |
Why?
|
| Injections, Subcutaneous | 3 | 2013 | 685 | 0.290 |
Why?
|
| Osteoblastoma | 1 | 2005 | 27 | 0.290 |
Why?
|
| Adipokines | 1 | 2008 | 298 | 0.290 |
Why?
|
| Estramustine | 2 | 2005 | 35 | 0.280 |
Why?
|
| Incidence | 15 | 2015 | 20320 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3878 | 0.280 |
Why?
|
| Metabolome | 1 | 2012 | 859 | 0.280 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1819 | 0.270 |
Why?
|
| Watchful Waiting | 3 | 2015 | 451 | 0.260 |
Why?
|
| Survival Rate | 14 | 2016 | 13202 | 0.260 |
Why?
|
| Proportional Hazards Models | 13 | 2015 | 12292 | 0.260 |
Why?
|
| Time Factors | 19 | 2017 | 41038 | 0.260 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 329 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6765 | 0.260 |
Why?
|
| Placebos | 5 | 2014 | 1733 | 0.250 |
Why?
|
| Spinal Cord | 1 | 2012 | 1831 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2012 | 10857 | 0.240 |
Why?
|
| Fatigue | 2 | 2008 | 1450 | 0.240 |
Why?
|
| Risk Factors | 22 | 2017 | 69553 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 1513 | 0.230 |
Why?
|
| Chromans | 1 | 2002 | 129 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2017 | 23950 | 0.220 |
Why?
|
| Administration, Oral | 4 | 2017 | 3944 | 0.220 |
Why?
|
| Lipids | 3 | 2008 | 3246 | 0.220 |
Why?
|
| Salvage Therapy | 3 | 2016 | 1296 | 0.220 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 813 | 0.220 |
Why?
|
| Exercise Therapy | 1 | 2009 | 901 | 0.220 |
Why?
|
| Endocrinology | 1 | 2007 | 414 | 0.210 |
Why?
|
| Prospective Studies | 17 | 2014 | 50597 | 0.210 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 11126 | 0.210 |
Why?
|
| Adipose Tissue | 4 | 2014 | 3234 | 0.210 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2004 | 630 | 0.200 |
Why?
|
| Follow-Up Studies | 15 | 2017 | 39038 | 0.200 |
Why?
|
| Indazoles | 1 | 2022 | 292 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2004 | 2910 | 0.190 |
Why?
|
| Adult | 31 | 2022 | 211041 | 0.190 |
Why?
|
| SEER Program | 5 | 2014 | 1549 | 0.190 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 3 | 2014 | 100 | 0.190 |
Why?
|
| Kidney Neoplasms | 4 | 2012 | 3970 | 0.180 |
Why?
|
| Clodronic Acid | 2 | 2012 | 63 | 0.180 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 5045 | 0.180 |
Why?
|
| Vinblastine | 1 | 2000 | 505 | 0.180 |
Why?
|
| Cholesterol | 1 | 2008 | 2866 | 0.180 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4969 | 0.170 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 503 | 0.170 |
Why?
|
| Electric Impedance | 1 | 2002 | 657 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 2865 | 0.170 |
Why?
|
| Risk Assessment | 17 | 2012 | 23284 | 0.170 |
Why?
|
| Radiotherapy | 4 | 2011 | 1623 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3515 | 0.170 |
Why?
|
| Myocardial Infarction | 4 | 2012 | 11323 | 0.170 |
Why?
|
| Bone Resorption | 4 | 2010 | 746 | 0.170 |
Why?
|
| Prednisolone | 1 | 2019 | 339 | 0.170 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 6562 | 0.170 |
Why?
|
| Complementary Therapies | 2 | 2004 | 517 | 0.160 |
Why?
|
| Receptors, Androgen | 2 | 2015 | 1060 | 0.160 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10803 | 0.160 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2012 | 1493 | 0.160 |
Why?
|
| Prognosis | 12 | 2015 | 28919 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2017 | 9488 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7487 | 0.160 |
Why?
|
| Triazoles | 1 | 2002 | 910 | 0.150 |
Why?
|
| Odds Ratio | 5 | 2015 | 9754 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2006 | 1938 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 5197 | 0.140 |
Why?
|
| Survival Analysis | 6 | 2012 | 10507 | 0.140 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 12447 | 0.140 |
Why?
|
| Cohort Studies | 10 | 2016 | 39292 | 0.130 |
Why?
|
| Thiazoles | 1 | 2002 | 1510 | 0.130 |
Why?
|
| Radionuclide Imaging | 3 | 2014 | 2028 | 0.130 |
Why?
|
| Body Weight | 2 | 2010 | 4680 | 0.130 |
Why?
|
| Osteocalcin | 3 | 2008 | 277 | 0.130 |
Why?
|
| Procollagen | 2 | 2011 | 191 | 0.130 |
Why?
|
| Gynecomastia | 1 | 2014 | 89 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 4865 | 0.130 |
Why?
|
| Androstenols | 2 | 2010 | 25 | 0.130 |
Why?
|
| Piperidines | 1 | 2022 | 1582 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2006 | 2759 | 0.120 |
Why?
|
| Samarium | 1 | 2012 | 3 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2004 | 12005 | 0.120 |
Why?
|
| Carcinoma | 2 | 2016 | 2307 | 0.120 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2012 | 5 | 0.120 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3936 | 0.120 |
Why?
|
| Retrospective Studies | 17 | 2017 | 71483 | 0.120 |
Why?
|
| United States | 15 | 2014 | 67165 | 0.120 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 100 | 0.120 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2012 | 138 | 0.110 |
Why?
|
| Estradiol | 3 | 2007 | 1974 | 0.110 |
Why?
|
| Hydroxybutyrates | 1 | 2012 | 84 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2007 | 536 | 0.110 |
Why?
|
| Forecasting | 2 | 2016 | 2941 | 0.110 |
Why?
|
| Acid Phosphatase | 1 | 2011 | 155 | 0.110 |
Why?
|
| DNA Repair | 1 | 2022 | 2028 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 2734 | 0.110 |
Why?
|
| Pyrroles | 3 | 2014 | 1182 | 0.110 |
Why?
|
| Comorbidity | 3 | 2012 | 10339 | 0.110 |
Why?
|
| Hot Flashes | 1 | 2014 | 308 | 0.110 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2004 | 127 | 0.110 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 128 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2015 | 727 | 0.110 |
Why?
|
| Femur | 2 | 2012 | 1274 | 0.100 |
Why?
|
| Risk | 3 | 2014 | 9641 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 790 | 0.100 |
Why?
|
| Hip | 1 | 2012 | 253 | 0.100 |
Why?
|
| Depression | 2 | 2008 | 7202 | 0.100 |
Why?
|
| Algorithms | 2 | 2010 | 13647 | 0.100 |
Why?
|
| Indoles | 3 | 2014 | 1857 | 0.100 |
Why?
|
| Bile Acids and Salts | 1 | 2012 | 349 | 0.100 |
Why?
|
| Calcium, Dietary | 2 | 2004 | 518 | 0.100 |
Why?
|
| Breast Neoplasms | 8 | 2011 | 19800 | 0.090 |
Why?
|
| Hypogonadism | 2 | 2008 | 753 | 0.090 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 1346 | 0.090 |
Why?
|
| Haplotypes | 1 | 2016 | 2874 | 0.090 |
Why?
|
| Leg | 1 | 2014 | 1160 | 0.090 |
Why?
|
| Models, Biological | 2 | 2017 | 9907 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1238 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 1061 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 12183 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2015 | 2125 | 0.080 |
Why?
|
| Hyperaldosteronism | 1 | 2010 | 164 | 0.080 |
Why?
|
| Fractures, Malunited | 1 | 2008 | 80 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 11239 | 0.080 |
Why?
|
| Pain | 3 | 2014 | 4636 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2011 | 1812 | 0.080 |
Why?
|
| Lumbar Vertebrae | 2 | 2009 | 1817 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 2325 | 0.070 |
Why?
|
| Neoplasms | 3 | 2009 | 20172 | 0.070 |
Why?
|
| Kinetics | 2 | 2015 | 6796 | 0.070 |
Why?
|
| DNA, Antisense | 1 | 2005 | 48 | 0.070 |
Why?
|
| Estrogens | 2 | 2003 | 1511 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2014 | 2729 | 0.070 |
Why?
|
| Urologic Diseases | 1 | 2008 | 252 | 0.070 |
Why?
|
| DNA Damage | 1 | 2016 | 2459 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2945 | 0.070 |
Why?
|
| Advisory Committees | 1 | 2010 | 759 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2012 | 2680 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4425 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2008 | 325 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 709 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 1796 | 0.070 |
Why?
|
| Coronary Disease | 2 | 2012 | 6127 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 2303 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2007 | 777 | 0.070 |
Why?
|
| Diethylstilbestrol | 1 | 2004 | 90 | 0.070 |
Why?
|
| Spine | 1 | 2012 | 1102 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2012 | 2461 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 443 | 0.070 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 2708 | 0.070 |
Why?
|
| Cross-Sectional Studies | 5 | 2008 | 23020 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 340 | 0.060 |
Why?
|
| Ureteral Neoplasms | 1 | 2004 | 87 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2016 | 2968 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 1422 | 0.060 |
Why?
|
| Diagnostic Imaging | 3 | 2014 | 3495 | 0.060 |
Why?
|
| Antimetabolites | 1 | 2003 | 127 | 0.060 |
Why?
|
| Drug Contamination | 1 | 2004 | 151 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 1999 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 16008 | 0.060 |
Why?
|
| Age Factors | 3 | 2016 | 18712 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2006 | 1156 | 0.060 |
Why?
|
| Female | 22 | 2016 | 375205 | 0.060 |
Why?
|
| Edema | 1 | 2006 | 744 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2014 | 1490 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2011 | 6451 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 2951 | 0.060 |
Why?
|
| Causality | 1 | 2008 | 1137 | 0.060 |
Why?
|
| Adolescent | 2 | 2022 | 84718 | 0.060 |
Why?
|
| Multiple Myeloma | 3 | 2009 | 5044 | 0.060 |
Why?
|
| Serenoa | 1 | 2001 | 11 | 0.060 |
Why?
|
| Biopsy | 2 | 2011 | 6766 | 0.060 |
Why?
|
| Syndrome | 1 | 2008 | 3177 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2009 | 1283 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1081 | 0.050 |
Why?
|
| Cell Separation | 1 | 2007 | 1835 | 0.050 |
Why?
|
| Alendronate | 1 | 2003 | 175 | 0.050 |
Why?
|
| Survivors | 2 | 2012 | 2149 | 0.050 |
Why?
|
| Carboplatin | 1 | 2005 | 797 | 0.050 |
Why?
|
| Flushing | 1 | 2001 | 50 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2009 | 843 | 0.050 |
Why?
|
| Hypericum | 1 | 2001 | 61 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 1817 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 1206 | 0.050 |
Why?
|
| Acupuncture | 1 | 2001 | 92 | 0.050 |
Why?
|
| Anthropometry | 1 | 2006 | 1367 | 0.050 |
Why?
|
| Neutrophils | 1 | 2014 | 3867 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2005 | 736 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2003 | 542 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1228 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2005 | 999 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2878 | 0.050 |
Why?
|
| Coronary Artery Disease | 2 | 2010 | 6213 | 0.050 |
Why?
|
| Weight Gain | 1 | 2010 | 2193 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2004 | 837 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 392 | 0.050 |
Why?
|
| African Americans | 2 | 2013 | 5118 | 0.050 |
Why?
|
| Animals | 6 | 2015 | 170486 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1148 | 0.050 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1537 | 0.050 |
Why?
|
| Thalidomide | 1 | 2005 | 919 | 0.050 |
Why?
|
| Triglycerides | 1 | 2008 | 2564 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 1829 | 0.050 |
Why?
|
| Pelvic Bones | 1 | 2001 | 271 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 254 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2009 | 4883 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 2029 | 0.050 |
Why?
|
| Rats | 2 | 2008 | 25094 | 0.050 |
Why?
|
| Vitamin D | 1 | 2013 | 3138 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2001 | 307 | 0.040 |
Why?
|
| Pyrazines | 1 | 2005 | 1259 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2002 | 7994 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 13536 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 8014 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2011 | 5141 | 0.040 |
Why?
|
| Dyspnea | 1 | 2006 | 1237 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2005 | 4057 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 632 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 2351 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 963 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 14836 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2010 | 2098 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3308 | 0.040 |
Why?
|
| Ketoconazole | 2 | 2010 | 100 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 688 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2001 | 456 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2012 | 2029 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2017 | 1688 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 3776 | 0.040 |
Why?
|
| Health Promotion | 1 | 2010 | 2172 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 2001 | 511 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8896 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2002 | 914 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2001 | 731 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3696 | 0.040 |
Why?
|
| Canada | 2 | 2013 | 1915 | 0.040 |
Why?
|
| Health Status | 1 | 2009 | 4015 | 0.040 |
Why?
|
| Inflammation | 2 | 2014 | 10019 | 0.040 |
Why?
|
| Cell Division | 1 | 2003 | 4752 | 0.040 |
Why?
|
| Osteolysis | 2 | 2007 | 266 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2007 | 15252 | 0.030 |
Why?
|
| Food-Drug Interactions | 1 | 2014 | 26 | 0.030 |
Why?
|
| Collagen | 1 | 2004 | 2687 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2000 | 0.030 |
Why?
|
| Gossypol | 1 | 2014 | 27 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 2927 | 0.030 |
Why?
|
| Densitometry | 2 | 2004 | 171 | 0.030 |
Why?
|
| Morbidity | 2 | 2010 | 1690 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 4831 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 405 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 628 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2015 | 509 | 0.030 |
Why?
|
| Boston | 1 | 2007 | 9402 | 0.030 |
Why?
|
| Michigan | 1 | 2014 | 330 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2014 | 3510 | 0.030 |
Why?
|
| Cell Survival | 1 | 2003 | 6156 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2003 | 2067 | 0.030 |
Why?
|
| Anemia | 1 | 2001 | 1403 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2008 | 8528 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 413 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 813 | 0.030 |
Why?
|
| Disease Management | 1 | 2003 | 2536 | 0.030 |
Why?
|
| Radiography | 2 | 2014 | 6989 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2371 | 0.030 |
Why?
|
| Sunlight | 1 | 2013 | 324 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2001 | 1356 | 0.030 |
Why?
|
| Life Style | 1 | 2003 | 3636 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2006 | 6255 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2015 | 877 | 0.030 |
Why?
|
| Insulin | 1 | 2006 | 6648 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3968 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2010 | 60 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 285 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9256 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 1276 | 0.020 |
Why?
|
| California | 1 | 2014 | 1392 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 464 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 629 | 0.020 |
Why?
|
| Calcium | 1 | 2003 | 5825 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 695 | 0.020 |
Why?
|
| Brachytherapy | 2 | 2010 | 1298 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1608 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 582 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 112 | 0.020 |
Why?
|
| Nomograms | 1 | 2010 | 225 | 0.020 |
Why?
|
| Hawaii | 1 | 2007 | 114 | 0.020 |
Why?
|
| Mutation | 2 | 2016 | 29262 | 0.020 |
Why?
|
| Age Distribution | 2 | 2004 | 2876 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 4116 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 177 | 0.020 |
Why?
|
| Threonine | 1 | 2007 | 277 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 16959 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2008 | 370 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3714 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3104 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2040 | 0.020 |
Why?
|
| Histidine | 1 | 2007 | 330 | 0.020 |
Why?
|
| Leucine | 1 | 2007 | 591 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 953 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2014 | 2042 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 434 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2014 | 1066 | 0.020 |
Why?
|
| Prevalence | 1 | 2002 | 14712 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2008 | 15053 | 0.020 |
Why?
|
| American Heart Association | 1 | 2010 | 973 | 0.020 |
Why?
|
| Estradiol Congeners | 1 | 2004 | 30 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2005 | 153 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1472 | 0.020 |
Why?
|
| Palliative Care | 2 | 2014 | 3261 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 2159 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1192 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 1906 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3156 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 2320 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2004 | 114 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 2100 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20308 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 1179 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2013 | 1820 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2010 | 1116 | 0.020 |
Why?
|
| Tyrosine | 1 | 2007 | 1477 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 2561 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7644 | 0.010 |
Why?
|
| Finasteride | 1 | 2003 | 88 | 0.010 |
Why?
|
| Microfluidics | 1 | 2007 | 599 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2010 | 1134 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4677 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 914 | 0.010 |
Why?
|
| Creatinine | 1 | 2007 | 1885 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3179 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 3330 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 3490 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3701 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 1730 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4306 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4317 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2007 | 21194 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 2503 | 0.010 |
Why?
|
| Registries | 1 | 2014 | 7989 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3690 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 1655 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 5041 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 732 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 1440 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 7763 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 5182 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 4293 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13468 | 0.010 |
Why?
|
| Kidney | 1 | 2004 | 6888 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 80876 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 55940 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 19423 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 17218 | 0.000 |
Why?
|